DAX19.909 -0,4%ESt504.896 +0,6%Top 10 Crypto14,72 -0,2%Dow42.544 -0,1%Nas19.311 -0,9%Bitcoin90.702 +0,4%Euro1,0350 ±-0,0%Öl74,83 +0,6%Gold2.625 ±-0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Tesla A1CX3T MicroStrategy 722713 Amazon 906866 Apple 865985 Microsoft 870747 Palantir A2QA4J Allianz 840400 Novo Nordisk A3EU6F Lilium A3CYXP Bayer BAY001 Volkswagen (VW) vz. 766403 BASF BASF11 Rheinmetall 703000 Deutsche Telekom 555750
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet letzten Handelstag 2024 tiefer -- Siemens nimmt Healthineers-Beteiligung unter die Lupe -- BayWa vereinbart Rettungsplan -- Tesla, Boeing im Fokus
Top News
Wechsel an der Spitze der Deutschen Börse: Stephan Leithner neuer CEO Wechsel an der Spitze der Deutschen Börse: Stephan Leithner neuer CEO
Netflix: Zweite 'Squid Game'-Staffel fulminant gestartet Netflix: Zweite 'Squid Game'-Staffel fulminant gestartet
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

CSL Aktie

NeuKaufenVerkaufen
83,00 EUR -0,50 EUR -0,60 %
FSE
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone
KGV36,04Div. Rendite1,24%

WKNA115DF

ISINUS12637N2045

SymbolCSLLY

CSL Aktien News

DatumMeistgelesen
PR NewswireCSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics
PR NewswireCSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Tr...
PR NewswireU.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B
PR NewswireNext-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022
PR NewswireCSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
PR NewswireCSL Plasma Expands in California with New Donation Centers to Collect Life-Saving Plasma
PR NewswireCSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine
PR NewswireCSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates
PR NewswireNew Canadian Surveys Highlight Influenza Education, Discussions with Healthcare Professionals, and Ease of Access as Critical to Supporting Vaccination Uptake
PR NewswireNew Canadian Surveys Highlight Influenza Education, Discussions with Healthcare Professionals, and Ease of Access as Critical to Supporting Vaccination Uptake
PR NewswireNew Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination Rates
PR NewswireNew Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems
PR NewswireCSL presents new research and development center in Marburg, Germany
PR NewswireCSL Seqirus to Highlight Commitment to Influenza Protection with More than 20 Data Presentations at OPTIONS XI
PR NewswireCSL Plasma Provides Free Flu Vaccines to U.S. Plasma Donors
PR NewswireCSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)
Dow JonesMÄRKTE ASIEN/Freundlich - Tokio auf Siebenmonatshoch
PR NewswireCSL announces carbon emissions reduction targets
PR NewswireCSL announces carbon emissions reduction targets
PR NewswireCSL FÜHRT NEUE EINHEITLICHE GLOBALE MARKENIDENTITÄT EIN
PR NewswireCSL LAUNCHES NEW UNIFIED GLOBAL BRAND IDENTITY
PR NewswireCSL LAUNCHES NEW UNIFIED GLOBAL BRAND IDENTITY
PR NewswireCSL Plasma Reimagines Donor Experience With First Donations Completed on Innovative Plasma Collection Technology
PR NewswireSeqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2022/23 U.S. Season
PR NewswireCDC Advisory Committee Includes FLUAD® QUADRIVALENT as a Preferentially Recommended Influenza Vaccine for Adults 65 and Older
PR NewswireAcclaimed Photographer Rankin and CSL Behring Team Up to Launch 'Portraits of Progress', an Exhibition Chronicling the Past, Present and Future of Life with Hemophilia
PR NewswireSeqirus Completes $156 Million Expansion to Holly Springs Manufacturing Facility, Optimizing Global Manufacturing Capabilities for Seasonal and Pandemic Influenza Vaccines
PR NewswireSeqirus' Holly Springs Manufacturing Facility Designated by U.S. Government as Pandemic Ready
PR NewswireFDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review
PR NewswireWalter Charles Named Senior Vice President and General Manager of CSL Plasma
PR NewswireCSL Behring Donates 500 Million International Units of Coagulation Factor Replacement Therapy to the World Federation of Hemophilia Humanitarian Aid Program to Help Those Living with Bleeding Diso...
PR NewswireEuropean Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B
PR NewswireEuropean Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B
PR NewswireForbes Magazine Ranks Global Biotech Leader CSL Among America's Best Employers for 2022
PR NewswireSeqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response
PR NewswireCSL Plasma Makes $125,000 Donation to American Red Cross for Disaster Relief in U.S. Communities
Dow JonesMÄRKTE ASIEN/Mehrheitlich fester - Ukraine-Krise und Fed-Protokoll im Blick
Dow JonesMÄRKTE ASIEN/Kräftige Gewinne mit leichter Entspannung in Ukraine-Krise
Dow JonesMÄRKTE ASIEN/Leichte Entspannung in Ukraine-Krise sorgt für Gewinne
PR NewswireSeqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine Technology

CSL News

CSL News: auf dieser Seite finden Sie alle CSL News und Nachrichten zur CSL Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch CSL News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um CSL News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.